Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent
1980-06-06
1983-06-28
Rosen, Sam
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reduced antigenicity, reduced ability to bind complement, or...
4242485, 42424852, 42424853, 42424854, 42424855, 424263, 424273R, 424274, 424275, 424309, 424320, 424324, A61K 3700
Patent
active
043905269
ABSTRACT:
The present invention relates to novel compounds selected from R.sub.1 --COO(CH.sub.2).sub.n --R.sub.2 and ##STR1## wherein R.sub.1 is selected from heterocyclic aromatic and hydrophobic naturally occuring and modified amino acids in the D- and in the L-form, and from peptides, wherein n is an integer of from 1 to 5 and R.sub.2 is selected from unsubstituted and substituted phenyl rings, and from heterocyclic rings, as well as to pharmaceutical compositions for preventing sickling of erythrocytes during sickle cell crisis and for desickling of sickle cells of patients afflicted by sickle cell disease, the active ingredient of which is a compound as defined above.
REFERENCES:
patent: 3466321 (1969-09-01), Morrew
patent: 3714228 (1973-01-01), Massie
patent: 3983138 (1976-09-01), Saari
patent: 4243819 (1981-01-01), Henrick et al.
Shirahawa et al.-Chem. Abst., vol. 93, (1980), p. 125443y.
Stuetz et al.-Chem. Abst., vol. 82, (1975), p. 156,375e.
Maclaren-Chem. Abst., vol. 77, (1972), p. 34902a.
Acquaye Clemenceau T. A.
Gorecki Marian
Rich Alexander
Wilchek Meir
Rosen Sam
Yeda Research & Development Co. Ltd.
LandOfFree
Pharmaceutical agents for the treatment of sickle cell disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical agents for the treatment of sickle cell disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical agents for the treatment of sickle cell disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-933259